Allogene Therapeutics Stock Earnings Per Share
| ALLO Stock | USD 2.52 0.24 10.53% |
Allogene Therapeutics fundamentals help investors to digest information that contributes to Allogene Therapeutics' financial success or failures. It also enables traders to predict the movement of Allogene Stock. The fundamental analysis module provides a way to measure Allogene Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Allogene Therapeutics stock.
Allogene | Earnings Per Share |
Allogene Therapeutics Company Earnings Per Share Analysis
Allogene Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Allogene Therapeutics Earnings Per Share | (1.55) X |
Most of Allogene Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Allogene Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Allogene Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Allogene Therapeutics is extremely important. It helps to project a fair market value of Allogene Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Allogene Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Allogene Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Allogene Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Allogene Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Allogene Therapeutics has an Earnings Per Share of -1.55 times. This is 118.52% lower than that of the Biotechnology sector and 67.64% lower than that of the Health Care industry. The earnings per share for all United States stocks is 149.68% higher than that of the company.
Allogene Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Allogene Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Allogene Therapeutics could also be used in its relative valuation, which is a method of valuing Allogene Therapeutics by comparing valuation metrics of similar companies.Allogene Therapeutics is currently under evaluation in earnings per share category among its peers.
Allogene Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Allogene Therapeutics from analyzing Allogene Therapeutics' financial statements. These drivers represent accounts that assess Allogene Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Allogene Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.6B | 3.0B | 2.0B | 900.4M | 503.8M | 478.6M | |
| Enterprise Value | 2.1B | 2.1B | 1.3B | 419.0M | 515.7M | 489.9M |
Allogene Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Allogene Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Allogene Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Allogene Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 271.62 M | ||||
| Shares Outstanding | 209.67 M | ||||
| Shares Owned By Insiders | 17.43 % | ||||
| Shares Owned By Institutions | 80.20 % | ||||
| Number Of Shares Shorted | 37.04 M | ||||
| Price To Earning | (3.30) X | ||||
| Price To Book | 1.03 X | ||||
| Price To Sales | 12,288 X | ||||
| Revenue | 95 K | ||||
| Gross Profit | 243 K | ||||
| EBITDA | (300.29 M) | ||||
| Net Income | (327.26 M) | ||||
| Cash And Equivalents | 490.49 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 95.12 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 11.42 X | ||||
| Book Value Per Share | 2.21 X | ||||
| Cash Flow From Operations | (237.73 M) | ||||
| Short Ratio | 20.05 X | ||||
| Earnings Per Share | (1.55) X | ||||
| Price To Earnings To Growth | (4.18) X | ||||
| Target Price | 9.04 | ||||
| Number Of Employees | 232 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 528.37 M | ||||
| Total Asset | 642.84 M | ||||
| Retained Earnings | (1.56 B) | ||||
| Working Capital | 422.04 M | ||||
| Current Asset | 418.72 M | ||||
| Current Liabilities | 26.36 M | ||||
| Net Asset | 642.84 M |
About Allogene Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Allogene Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Allogene Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Allogene Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Allogene Stock
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Allogene Therapeutics Piotroski F Score and Allogene Therapeutics Altman Z Score analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.